Coronavirus

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Staff November 12, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing...

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Staff November 11, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it...

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Staff November 10, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it...

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Staff November 6, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology...

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Staff November 5, 2025

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT /...

Aligos Therapeutics to Present at Upcoming Investor Conferences

Staff November 4, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Staff November 3, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Staff October 30, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Staff October 29, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"),...

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Staff October 28, 2025

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from...

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Staff October 28, 2025

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical...

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Staff October 27, 2025

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Staff October 27, 2025

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Staff October 27, 2025

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Staff October 27, 2025

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Staff October 27, 2025

BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Staff October 27, 2025

BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Staff October 27, 2025

BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Staff October 22, 2025

SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"),...

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Staff October 20, 2025

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...

Coronavirus

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Aligos Therapeutics to Present at Upcoming Investor Conferences

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Awake Breast Augmentation: Gruber Plastic Surgery Highlights Live Implant Sizing Under Local Anesthesia With No Sedation for Eligible Patients

Clemson University and Nordic Wellness Launch Groundbreaking Partnership to Transform the Student Mental Health Crisis

Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season

Vireo Growth Inc. to Acquire Additional Outstanding Senior Secured Convertible Notes of Schwazze

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

You may have missed